Sylvia B Bartel1. 1. Dana-Farber Cancer Institute, Pharmacy Department, 44 Binney Street, Dana Building, Room DL294, Boston, MA 02115, USA. sylvia_bartel@dfci.harvard.edu
Abstract
PURPOSE: Safe handling practices and financial concerns associated with oral chemotherapy in non-traditional settings are discussed. SUMMARY: Oral chemotherapy may pose a risk to patients because of a narrow therapeutic index, complex dosing regimen, dispensing by community pharmacists without prescription order review by an oncology pharmacist or nurse, or self-administration in the home or another nontraditional setting, where patient monitoring is infrequent. Errors in prescribing, dispensing, and administration and patient or caregiver misunderstandings are potential problems with the use of oral chemotherapy that need to be addressed when developing safe practices. Changes in Medicare pharmaceutical reimbursement rates and rules need to be monitored because they have the potential to affect patient care and outcomes. Patient assistance programs and advocacy groups can help alleviate financial concerns associated with oral chemotherapy. CONCLUSION: Consensus guidelines specific to safe handling of oral chemotherapy in the home or other nontraditional setting need to be developed. Also, healthcare providers must understand reimbursement and provide direction to patients when patient assistance programs or advocacy groups can assist with the financial challenges of oral chemotherapy.
PURPOSE: Safe handling practices and financial concerns associated with oral chemotherapy in non-traditional settings are discussed. SUMMARY: Oral chemotherapy may pose a risk to patients because of a narrow therapeutic index, complex dosing regimen, dispensing by community pharmacists without prescription order review by an oncology pharmacist or nurse, or self-administration in the home or another nontraditional setting, where patient monitoring is infrequent. Errors in prescribing, dispensing, and administration and patient or caregiver misunderstandings are potential problems with the use of oral chemotherapy that need to be addressed when developing safe practices. Changes in Medicare pharmaceutical reimbursement rates and rules need to be monitored because they have the potential to affect patient care and outcomes. Patient assistance programs and advocacy groups can help alleviate financial concerns associated with oral chemotherapy. CONCLUSION: Consensus guidelines specific to safe handling of oral chemotherapy in the home or other nontraditional setting need to be developed. Also, healthcare providers must understand reimbursement and provide direction to patients when patient assistance programs or advocacy groups can assist with the financial challenges of oral chemotherapy.
Authors: Susan Goodin; Niesha Griffith; Beth Chen; Karen Chuk; Mikael Daouphars; Christian Doreau; Rinku A Patel; Rowena Schwartz; Maria José Tamés; Robert Terkola; Barbara Vadnais; Debbie Wright; Klaus Meier Journal: J Oncol Pract Date: 2011-01 Impact factor: 3.840
Authors: Sultan Kav; Lisa Schulmeister; Anita Nirenberg; Linda Barber; Judi Johnson; Cynthia Rittenberg Journal: Support Care Cancer Date: 2009-07-10 Impact factor: 3.603
Authors: Manvi Sharma; Holly M Holmes; Hemalkumar B Mehta; Hua Chen; Rajender R Aparasu; Ya-Chen T Shih; Sharon H Giordano; Michael L Johnson Journal: Cancer Date: 2019-01-03 Impact factor: 6.860